ArticleArthritis research & therapy2026
Cyclovirobuxine D attenuates collagen-induced arthritis by inhibiting PI3K/AKT pathway and macrophage polarization.
Article in Arthritis research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Conventional therapeutic interventions for rheumatoid arthritis (RA) are frequently induced immunosuppressive side effects. The present study explores the therapeutic potential of Cyclovirobuxine D (CycD), a triterpenoid alkaloid isolated from Buxus microphylla, in a collagen-induced arthritis (CIA) mouse model or in vitro. The CIA model was treated with varying doses of CycD or methotrexate. The biomarkers of inflammatory factors related to macrophage polarization and oxidative stress in serum or synovial tissue was conducted. The RNA sequencing (RNA-seq) was employed to identify key post-regulatory genes in CycD treatment. The pathway was investigated using PI3K activators and inhibitors, both in vivo and vitro. Molecular docking, Network Pharmacology, Drug Affinity Responsive Target Stability (DARTS) and Cellular Thermal Shift Assay (CETSA) were performed to validate. The administration of CycD resulted in a substantial alleviation arthritis severity, joint pathology, and levels of biomarkers associated with macrophage polarization and oxidative stress in CIA mice. In contrast to methotrexate, CycD exhibited minimal adverse effects on the spleen and thymus. RNA-seq and immunofluorescent staining has showed that the biological function of CycD is predominantly characterized by its capacity to suppress the PI3K-AKT pathway in M1 macrophages. The activation of PI3K was found to counteract the therapeutic benefits of CycD in both CIA mice, RAW264.7 and THP-1 cells. Molecular docking, Network Pharmacology, DARTS and CETSA confirmed that CycD competes with PI3K for binding in M1-type macrophages. CycD alleviates collagen-induced arthritis by inhibiting the PI3K-AKT pathway in macrophages.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.